Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Howard Herrmann

Interventional Cardiology Philadelphia, PA Medical Doctor

NPI 1679503783 CMS profile 212120

3400 Civic Center Blvd Fl 2, Fl 11, Philadelphia, PA 19104

Open in the dashboard

General payments

$258,645

412 records reported · program years 2019–2025

Research payments

$48,856

Paid to them · 51 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,975,856 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Howard Herrmann of Philadelphia, PA is reported in the CMS Open Payments database as having received $258,645 across 412 general payments and $48,856 in research payments paid to them. Separately, studies naming them as principal investigator received $1,975,856 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $90,144 101
2025 Research $1,513 3
2024 General $77,818 108
2024 Research $4,969 12
2023 General $9,986 37
2023 Research $7,781 12
2022 General $15,700 54
2022 Research $16,031 12
2021 General $23,301 20
2021 Research $11,344 11
2020 General $18,112 34
2020 Research $7,219 1
2019 General $23,584 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Howard Herrmann
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Howard Herrmann were reported at $90,144. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Howard Herrmann Interventional Cardiology median Middle half National median
2019 $23,584 $1,097 $329–$3,048 $163
2020 $18,112 $473 $161–$1,480 $114
2021 $23,301 $677 $233–$1,827 $132
2022 $15,700 $978 $333–$2,724 $149
2023 $9,986 $1,136 $382–$2,986 $160
2024 $77,818 $1,181 $395–$3,326 $164
2025 $90,144 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $201,835 247 payments
  2. Medtronic Vascular, Inc. $27,648 45 payments
  3. Edwards Lifesciences Corporation $14,674 43 payments
  4. Abbott Laboratories $8,472 32 payments
  5. Shockwave Medical, Inc $3,375 11 payments
  6. Biosense Webster, Inc. $1,101 2 payments
  7. Boston Scientific Corporation $357 6 payments
  8. CathWorks, Inc. $289 3 payments
  9. Penumbra, Inc. $276 4 payments
  10. Abiomed $264 7 payments
  11. Other $353 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $171,425 71 payments
  2. Consulting Fee $40,000 17 payments
  3. Travel and Lodging $27,816 93 payments
  4. Food and Beverage $12,230 227 payments
  5. Honoraria $4,361 1 payment
  6. Compensation for serving as faculty or as a speaker for a medical education program $2,500 1 payment
  7. Education $225 1 payment
  8. Grant $89 1 payment
Products named General payments · program years 2019–2025
  1. COREVALVE EVOLUT R $169,986 179 payments
  2. CoreValve Evolut Transcatheter Valve Systems $19,407 25 payments
  3. CoreValve Evolut Transcatheter Valve Systems $15,582 11 payments
  4. Resolute $8,241 20 payments
  5. Vascular Lithotripsy $3,125 2 payments
  6. MITRACLIP Vascular $2,193 3 payments
  7. MITRACLIP Vascular $2,185 5 payments
  8. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $2,042 5 payments
  9. Mitra Clip system $1,750 2 payments
  10. TRICLIP $1,662 9 payments
  11. Other $8,277 111 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $41,638 50 payments
  2. Medtronic Vascular, Inc. $7,219 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

82

Median for Interventional Cardiology: 2,236

Drug cost

$18,062

Median for Interventional Cardiology: $380,412

Branded share of claims

20.7%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 17 $17,151
Rosuvastatin Calcium Generic 16 $345
Metoprolol Succinate Generic 26 $316
Furosemide Generic 12 $157
Losartan Potassium Generic 11 $92

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$111,981

Medicare's payments for the services billed

Medicare patients

400

Average age 76

Services billed

1,168

157 women, 243 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 68%
Heart failure 56%
Atrial fibrillation 48%
Arthritis 48%
Chronic kidney disease 47%
Diabetes 38%
COPD 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

463 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record